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Original Article
Purpose: We aimed to analyze the treatment outcome and long-term toxicity of 70 Gy hypofractionated intensity-modulated 
radiotherapy (IMRT) for localized prostate cancer using a customized rectal balloon.
Materials and Methods: We reviewed medical records of 86 prostate cancer patients who received curative radiotherapy 
between January 2004 and December 2011 at our institution. Patients were designated as low (12.8%), intermediate (20.9%), or 
high risk (66.3%). Thirty patients received a total dose of 70 Gy in 28 fractions over 5 weeks via IMRT (the Hypo-IMRT group); 56 
received 70.2 Gy in 39 fractions over 7 weeks via 3-dimensional conformal radiotherapy (the CF-3DRT group, which served as a 
reference for comparison). A customized rectal balloon was placed in Hypo-IMRT group throughout the entire radiotherapy course. 
Androgen deprivation therapy was administered to 47 patients (Hypo-IMRT group, 17; CF-3DRT group, 30). Late genitourinary (GU) 
and gastrointestinal (GI) toxicity were evaluated according to the Radiation Therapy Oncology Group criteria.
Results: The median follow-up period was 74.4 months (range, 18.8 to 125.9 months). The 5-year actuarial biochemical relapse-
free survival rates for low-, intermediate-, and high-risk patients were 100%, 100%, and 88.5%, respectively, for the Hypo-IMRT 
group and 80%, 77.8%, and 63.6%, respectively, for the CF-3DRT group (p < 0.046). No patient presented with acute or late GU 
toxicity ≥grade 3. Late grade 3 GI toxicity occurred in 2 patients (3.6%) in the CF-3DRT group and 1 patient (3.3%) in the Hypo-
IMRT group.
Conclusion: Hypo-IMRT with a customized rectal balloon resulted in excellent biochemical control rates with minimal toxicity in 
localized prostate cancer patients. 
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Introduction
The optimum radiation treatment schedule for localized 
prostate cancer remains unknown. Although recent dose-
escalation studies showed improved biochemical and local 
control rates [1-3], prolonging the radiation schedule increases 
the financial burdens and inconveniences for patients. How-
ever, studies that determines prostate cancer sensitivity to 
fractionation in radiotherapy treatments point to an α/β value 
around 2.7 Gy [4,5], which is lower than that required for late 
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rectal complications (5.4 ± 1.5 Gy) [6]. Thus, hypofractionation 
is an attractive option for treatment of localized prostate 
cancer. 
  Because of normal tissue tolerance, escalation of the total 
dose and fractional dose requires precise radiation delivery 
techniques, such as intensity-modulated radiotherapy (IMRT) 
and strict immobilization devices. Rectal balloons can be used 
to reduce treatment-related toxicity by sparing the posterior 
wall of the rectum [7,8] and to restrict prostate motion by 
minimizing both inter- and intra-fractional variations in rectal 
position. In our previous report, a customized rectal balloon 
showed reliable positional reproducibility [9]. 
  We have conducted hypofractionated IMRT (Hypo-IMRT, 
70 Gy in 2.5 Gy fractions) with a customized rectal balloon 
since 2004. In this study, we aimed to analyze the treatment 
outcome and long-term toxicity of this protocol. As a 
reference, the results of this treatment were compared with 
those of 70.2 Gy delivered via conventionally fractionated 
3-dimensional conformal radiotherapy (CF-3DRT).
Materials and Methods
1. Patients
Between January 2004 and December 2011, 86 patients with 
stages T1–T3b, N0–N1 localized prostate cancer were treated 
with definitive radiotherapy to a total dose of 70 Gy using 
a customized rectal balloon. Thirty patients received Hypo-
IMRT, and 56 patients received CF-3DRT. All patients had 
pathologically confirmed prostate adenocarcinoma, acinar 
type. Patients who had previously received radiotherapy to 
the pelvis were excluded. On the basis of the Memorial Sloan 
Kettering Cancer Center risk grouping criteria, patients were 
divided into 3 prognostic groups as follows: low risk (initial 
PSA ≤10.0 ng/mL; Gleason score [GS], 2–6; Stage T1a–T2b), 
intermediate risk (initial PSA >10.0 ng/mL or GS ≥7 or Stage 
≥T2c), and high risk (2 or 3 of the intermediate risk factors) 
[10]. The pretreatment evaluation consisted of a complete 
medical history, a digital rectal exam, a whole-body bone scan, 
a computed tomography (CT) scan of the abdomen and pelvis, 
magnetic resonance imaging of the prostate, and laboratory 
tests including measurement of serum prostate-specific 
antigen (PSA) levels.
2. Radiotherapy
All patients were instructed to empty their rectum by self-
administered enemas. Patients underwent CT simulation in 
the supine position after immobilization with a vacuum body 
fixation device. In order to minimize the effects of bladder 
motion, the bladder was filled for a specific period of time 
within a comfortable range for the patient. 
  Target volumes were defined as follows: gross tumor volume 
(GTV) included the prostate gland and any extraprostatic gross 
tumor and involved lymph nodes. Clinical target volume 1 
(CTV1) included periprostatic fat tissue and proximal seminal 
vesicles, and CTV2 included the distal seminal vesicles and 
pelvic lymph nodes. Planning target volume 1 (PTV1) was 
defined as GTV plus a 5-mm margin in all directions except 
posteriorly, which had only a 2-mm margin to minimize rectal 
mucosal exposure. PTV2 and PTV3 were defined as CTV1 and 
CTV2, respectively, plus a 3-mm margin. 
  Total doses of 70 Gy (2.5 Gy/fraction), 60.2 Gy (2.15 Gy/
fraction), and 50.4 Gy (1.8 Gy/fraction) in 28 fractions were 
the prescribed dose-volumes for PTV1, PTV2, and PTV3, 
respectively. Assuming an α/β ratio of 3 Gy, the doses delivered 
for PTV1, PTV2, and PTV3 via Hypo-IMRT equate to a 1.8 Gy-
equivalent dose of 81 Gy, 64.8 Gy, and 50.4 Gy, respectively. We 
applied rectal balloons to Hypo-IMRT patients at the beginning 
since the hypofractionated regimen reduces the treatment 
period by more than 2 weeks. Elective pelvic lymph node 
irradiation was performed only when the possibility of pelvic 
lymph node metastasis was greater than 30%, as predicted 
by the Roach score for lymph node metastasis (RSLN)—based 
on the equation, 2/3 PSA + (GS − 6) × 10 [11]. In patients 
with an RSLN of 30% or less, the pelvic lymph node chain 
was excluded from the PTV3. Eight patients underwent linac-
based IMRT, and the others underwent helical tomotherapy. 
Linac-based IMRT was planned using the Corvus (Nomos Corp., 
Pittsburg, PA, USA) system, and helical tomotherapy using the 
Hi-Art (TomoTherapy Inc., Madison, WI, USA) planning station. 
The criterion for planning the PTV was that at least 95% of it 
should be covered by 95% of the prescribed dose. The dose-
volume constraints for normal tissues in the rectum were 
as follows: less than 60% of the volume received 30 Gy, less 
than 15% received 60 Gy, and less than 5% received 70 Gy. 
For normal tissues in the bladder, less than 50% of the volume 
received 20 Gy. Less than 10% of the femoral heads received 
40 Gy.
  CF-3DRT was planned using the ADAC Pinnacle3 system, and 
the fraction dose was 1.8 Gy. Distal seminal vesicles and/or 
pelvic lymph nodes were excluded through the first cone down 
at 45.0–50.4 Gy, and proximal seminal vesicle and periprostatic 
fat were excluded through the second cone down at 59.4 Gy. 
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We prescribed up to 70.2 Gy for the GTV isocenter. In CF-3DRT 
group, the rectal balloon was not applied until the first cone 
down because it was thought that 39 fractions would be a 
burden to both the radiation therapist and the patient. 
  The dose statistics of the rectum and bladder are summarized 
according to the radiotherapy technique and field in Table 1.
3. Androgen deprivation therapy
Androgen deprivation therapy (ADT) was prescribed at the 
discretion of the treating urologist. In general, low- and 
intermediate-risk patients received a 4- to 6-month course 
of ADT, and high-risk patients received a 6-month to 2-year 
course of ADT before radiation therapy was considered. The 
median duration of ADT was 5.5 months (range, 0.73 to 93 
months); it was 5.8 months (range, 0.73 to 36.4 months) 
for the Hypo-IMRT group and 5.3 months (range, 0.73 to 93 
months) for the CF-3DRT group (p = 0.938).
  
4. Follow-ups and toxicities
All end points were calculated from the completion of the 
radiation treatment. Biochemical failure (BCF) was defined 
using the Phoenix consensus of the nadir of PSA concentration 
plus 2 ng/mL. Death was considered as cancer-specific if there 
was clear evidence that it occurred secondary to prostate 
cancer or if the patient had metastatic disease with an eleva-
ted PSA level at the time of death. 
  Acute and late toxicities were assessed using the Radiation 
Therapy Oncology Group morbidity criteria. Acute toxicity was 
defined as any new event occurring during radiotherapy or 
within 3 months after radiotherapy, and late toxicities as any 
event persisting for more than 3 months or occurring more 
than 3 months after radiotherapy. Patients were seen 3 and 6 
months after completion of radiotherapy and every 6 months 
thereafter.
5. Statistical analysis
Kaplan-Meier curves for biochemical relapse-free survival 
(BRFS) and overall survival were generated, and survival 
comparisons were made using the log-rank test. Clinical 
characteristics and toxicity grading among the treatment 
groups were compared using the chi-square test or Fisher 
exact test for categorical variables. Multivariable analysis 
was performed via a proportional hazards analysis, using 
prespecified categorical explanatory variables (e.g., clinical 
Table 1. Rectal and bladder dose statistics according to the radiotherapy technique and field
Hypo-IMRT CF-3DRT
Prostate (%) Prostate + WP (%) Prostate (%) Prostate + WP (%)
Rectum
    V5
    V10
    V55
    V60
    V65
    V70
    Dmean (Gy)
    Dmax (Gy)
Bladder
    V5
    V10
    V55
    V60
    V65
    V70
    Dmean (Gy)
    Dmax (Gy)
97.4 (93.0–100)
94.2 (89.0–100)
13.5 (0.5–21.0)
10.4 (0–15.0)
6.3 (0–10.0)
2.5 (0–5.0)
34.9 (28.3–43.5)
73.1 (71.1–78.7)
99.6 (98.0–100)
97.0 (90.0–100)
6.0 (1.0–17.0)
3.3 (0–10.0)
1.5 (0–4.0)
0.6 (0–1.5)
36.4 (31.7–43.1)
67.6 (56.1–79.7)
99.1 (95.0–100)
98.1 (92.5–100)
8.2 (1.0–18.0)
5.1 (0–14.0)
3.1 (0–10.0)
0.8 (0–2.5)
37.6 (32.9–42.2)
73.2 (67.8–78.0)
100
100
10.5 (2.0–20.0)
6.8 (1.0–15.0)
3.6 (1.0–7.0)
1.5 (0–4.0)
35.9 (16.0–46.4)
72.0 (58.6–79.9)
100
100
44.0 (34.0–68.2)
34.1 (28.0–46.0)
19.5 (15.0–35.0)
14.8 (8.2–22.0)
41.9 (38.6–53.1)
72.0 (70.2–76.3)
100
100
37.4 (30.5–50.2)
27.0 (28.0–46.0)
20.3 (15.0–28.0)
11.8 (8.2–16.0)
44.7 (38.6–54.2)
63.0 (60.2–76.3)
100
100
49.0 (34.8–66.2)
35.0 (24.3–57.8)
25.0 (17.0–35.7)
18.9 (10.8–23.6)
54.2 (38.0–60.1)
72.3 (69.8–78.3)
100
100
41.5 (36.0–56.2)
32.0 (24.3–53.8)
21.0 (16.0–32.7)
12.4 (11.3–22.7)
46.3 (39.1–58.3)
72.0 (60.8–74.3)
Values are presented as mean (range).
CF-3DRT, conventionally fractionated 3-dimensional conformal radiotherapy; Hypo-IMRT, hypofractionated intensity-modulated radio-
therapy; WP, whole pelvis; VX = organ percent volume receiving X Gy; Dmean, mean dose of the organ; Dmax, maximum dose of the organ.
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stage, GS, PSA, and radiation dose). Variables associated with 
late toxicity were evaluated using logistic regression. A p-value 
<0.05 was considered statistically significant. Statistical 
analysis was performed using SPSS ver. 20.0.0 software (SPSS 
Inc., Chicago, IL, USA). 
Results
1. Patients and treatments
Table 2 lists the characteristics and treatments of the patients. 
No significant differences were found in the age, clinical 
T stage, GS, nodal stage, initial PSA level, risk group, RSLN, 
radiotherapy field, or use of ADT between the Hypo-IMRT 
and CF-3DRT groups. The median PSA level at diagnosis was 
14.08 ng/mL (range, 3.6 to 180.2 ng/mL). The percentages of 
patients in the low-, intermediate-, and high-risk groups were 
12.8%, 20.9%, and 66.3%, respectively. RSLNs were divided 
into 2 categories based on cutoff values of 15%, which is 
traditionally used, and 30%. ADT was administered to 47 
patients, 17 (56.7%) in the Hypo-IMRT group and 30 (53.6%) 
Table 2. Characteristics and treatments of the patients
All (n = 86) Hypo-IMRT (n = 30) CF-3DRT (n = 56) p-value
Age (yr)
cT stage
    T1-T2a
    T2b-T2c
    T3a-T3b
Gleason score
    5–6
    7
    8–10
cN stage
    0
    1
Initial PSA
    ≤10
    >10, ≤20
    >20
Risk group
    Low
    Intermediate
    High
RSLN (%), 30
    >30
    ≤30
RSLN (%), 15
    >15
    ≤15
RT field
    Prostate
    WP
ADT
    No
    Yes
Duration (mo)
71.5 (55–88)
26 (30.2)
17 (19.8)
43 (50.0)
25 (29.1)
30 (34.9)
31 (36.0)
79 (91.9)
7 (8.1)
30 (34.9)
21 (24.4)
35 (40.7)
11 (12.8)
18 (20.9)
57 (66.3)
47 (54.7)
39 (45.3)
58 (67.4)
28 (32.6)
47 (54.7)
39 (45.3)
39 (45.3)
47 (54.7)
5.5 (0.73–93.0)
70.8 (60–79)
9 (30.0)
4 (13.3)
17 (56.6)
10 (33.3)
11 (36.7)
9 (30)
28 (93.3)
2 (6.7)
12 (40.0)
6 (20.0)
12 (40.0)
5 (16.6)
5 (16.6)
20 (66.7)
15 (50.0)
15 (50.0)
20 (66.7)
10 (33.3)
15 (50.0)
15 (50.0)
13 (43.3)
17 (56.7)
5.8 (0.73–36.4)
72 (55–88)
17 (30.4)
13 (23.2)
26 (46.4)
15 (26.8)
19 (33.9)
22 (39.3)
51 (91.1)
5 (8.9)
18 (21.1)
15 (26.8)
23 (41.1)
6 (10.7)
13 (23.2)
37 (66.1)
32 (57.1)
24 (42.9)
38 (67.8)
18 (32.2)
32 (57.1)
24 (42.9)
26 (46.4)
30 (53.6)
5.3 (0.73–93.0)
0.938
0.526
0.754
0.534
0.788
0.779
0.634
0.594
0.634
0.657
0.938
Values are presented as median (range) or number (%).
ADT, androgen-deprivation therapy; CF-3DRT, conventionally fractionated 3-dimensional conformal radiotherapy; cN, clinical nodal; cT, 
clinical tumor; Hypo-IMRT, hypofractionated intensity-modulated radiotherapy; PSA, prostate-specific antigen; RSLN, Roach score for 
prediction of lymph node metastasis; RT, radiotherapy; WP, whole pelvis.
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in the CF-3DRT group. The Hypo-IMRT group included 2 low-
risk (40% of all low-risk patients), 2 intermediate-risk (40% 
of all intermediate-risk patients), and 13 high-risk (65% of all 
high-risk patients) ADT recipients. The CF-3DRT group included 
1 low-risk (16.7%), 4 intermediate-risk (30.8%), and 25 high-
risk (67.6%) ADT recipients. 
2. Biochemical control and survival
The median follow-up time, defined as the interval from the 
completion of radiotherapy to the last PSA measurement, was 
74.4 months (range, 18.8 to 125.9 months); the median time 
was 73.4 months (range, 18.8 to 114.07 months) for the Hypo-
IMRT group and 78.6 months (range, 20 to 125.9 months) for 
the CF-3DRT group. The actuarial BRFS rate for all patients at 
5 years was 75.8%; it was 92.9% for the Hypo-IMRT group 
and 64.1% for the CF-3DRT group (log-rank, p < 0.046) (Fig. 1). 
The 5-year BRFS rates for low-, intermediate-, and high-risk 
patients were 100%, 100%, and 88.5%, respectively, for the 
Hypo-IMRT group and 80%, 77.8%, and 63.6%, respectively, 
for the CF-3DRT group (Fig. 2).
  A univariate analysis demonstrated that administration of 
ADT, an RSLN over 30, and EQD1.8 Gy3 were associated with 
biochemical outcome (Table 3). EQD1.8 Gy3 is defined as the 
1.8 Gy-equivalent dose, assuming an α/β ratio of 3 Gy. Men 
receiving ADT had an overall BRFS rate of 78.6% compared 
with 55.4% for men who did not receive ADT (p = 0.015). The 
5-year BRFS rates were 89.4% and 72.3% for ADT recipients 
in the hypo-IMRT group and CF-3DRT group, respectively. 
Men with an RSLN over 30 had a 5-year BRFS rate of 67.5% 
compared with 88.2% for men with an RSLN less than 30 (p 
= 0.019). In a multivariable analysis, administration of ADT 
(hazard ratio, 5.705; p = 0.002) and an RSLN over 30 (hazard 
ratio, 0.185; p = 0.005) were associated with biochemical 
outcome, whereas EQD1.8 Gy3 was not. 
  The overall survival rate was 87.9% at 5 years. No prostate 
cancer-specific deaths were observed in any of the risk groups. 
During the follow-up period, 12 patients died of pneumonia, 
heart failure, or accidental events. 
  
3. Analysis of biochemical failures
Three (10%) of the 30 patients in the Hypo-IMRT group 
experienced BCF. All 3 were high-risk patients. Two developed 
BCF 15 and 16 months after radiotherapy as their sole 
treatment; both received hormone therapy after BCF, one of 
whom developed sternal metastasis 85 months after treatment. 
The third patient experienced BCF 83 months after an initial 
5-month hormone treatment and subsequent radiotherapy. In 
the CF-3DRT group, 13 patients (23%) experienced BCF with a 
median time to failure of 42 months (range, 9 to 80 months). 
These included 1, 3, and 9 patients in the low-, intermediate-, 
and high-risk groups, respectively. The low- to intermediate-
risk patients received radiotherapy alone before BCF and 
hormone therapy after BCF. The high-risk patients experienced 
BCF at a median time of 30 months (range, 9 to 80 months). 
Among them, 4 had initially received radiotherapy alone, and 5 
had received combined hormone therapy and radiotherapy.
 
4. Late toxicity
The late toxicities of all patients are summarized in Table 4. 
The 5-year actuarial grade 2 or higher late gastrointestinal (GI) 
Fig. 1. Overall survival (A) and biochemical recurrence-free survival (B) for conventionally fractionated 3-dimensional conformal 
radiotherapy (CF-3DRT) and hypofractionated intensity-modulated radiotherapy (Hypo-IMRT).
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toxicity rate was 7%. Three patients experienced late grade 
3 GI toxicity, 2 (3.6%) in the CF-3DRT group and 1 (3.3%) in 
the Hypo-IMRT group. These patients were treated by argon 
plasma coagulation and are now symptom-free. Two patients 
(2.3%) experienced late genitourinary (GU) grade 2 toxicity, 
1 (1.8%) in the CF-3DRT group and 1 (3.3%) in the Hypo-
Table 3. Univariate and multivariate analysis for biochemical relapse free survival influencing factors
Variable
Univariate Multivariate
p-value HR (95% CI) p-value
Age (yr)
Risk group 
Gleason score
cT stage 
iPSA (ng/mL)
RSLN (%)
RT field 
EQD1.8 Gy3 
Use of ADT 
<70 vs. ≥70
Low vs. Intermediate vs. High
>7 vs. 7 vs. 7<
T1-T2a vs. T2b-T2c vs. T3
≤10 vs. >10 and ≤20 vs. >20
≤30 vs. >30
≤15 vs. >15
Whole pelvis vs. Prostate
81 vs. 70.2
Yes vs. No
0.514
0.818
0.578
0.242
0.210
0.019
0.371
0.300
0.046
0.015
-
-
-
-
-
0.185 (0.058–0.593)
-
-
2.257 (0.613–8.311)
   5.705 (1.880–17.315)
-
-
-
-
-
0.005
-
-
0.221
0.002
ADT, androgen deprivation therapy; cT, clinical tumor; EQD1.8 Gy3, 1.8 Gy equivalent dose, assuming an α/β ratio of 3 Gy; iPSA, initial 
prostate-specific antigen; RSLN, Roach score for prediction of lymph node metastasis; RT, radiotherapy; ADT, androgen deprivation 
therapy.
Fig. 2. Biochemical recurrence-free survival for conventionally 
fractionated 3-dimensional conformal radiotherapy (CF-3DRT) 
and hypofractionated intensity-modulated radiotherapy (Hypo-
IMRT) in the low-risk group (A), intermediate-risk group (B), and 
high-risk group (C).
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IMRT group. No grade 3 or higher GU complications were 
encountered. We performed a binary-logistic regression to 
identify the variables causing late GU and GI toxicity (Table 5). 
Patients who had experienced acute GI toxicity above grade 2 
during radiotherapy had a tendency of developing late grade 
2 GI toxicity or above (odds ratio, 2.547; 95% confidence 
interval, 0.983–6.602; p = 0.054).
Discussion and Conclusion
Our results revealed that an excellent 5-year BRFS rate of 
92.9% could be achieved when 70 Gy were delivered in 2.5-
Gy daily fractions via Hypo-IMRT for localized prostate cancer. 
Furthermore, although its biologically effective dose was 
higher than that of CF-3DRT, Hypo-IMRT resulted in similar or 
less GI and GU toxicities in the normal tissues. We attribute 
this enhancement of the therapeutic ratio to the improved 
isodose distribution of IMRT, the hypofractionation scheme, and 
the rectal immobilization and poseterior wall sparing achieved 
by a customized rectal balloon. To our knowledge, this is the 
first report of definitive radiotherapy performed together with 
a rectal balloon, using a dose escalated hypofractionation 
scheme in the management of localized prostate cancer in 
Korea.
  As a result of the several randomized control trials [12-14] 
of prostate cancer radiotherapy, we can expect that the dose-
Table 4. Crude incidence of maximum late genitourinary and gastrointestinal morbidity between men who received Hypo-IMRT and 
CF-3DRT
Toxicity
RTOG toxicity gradea)
p-value
0 1 2 3 4
Late GU
    CF-3DRT
    Hypo-IMRT
Late GI
    CF-3DRT
    Hypo-IMRT
49 (87.5)
25 (83.3)
50 (89.3)
27 (90.0)
  8 (14.3)
  4 (13.3)
2 (3.6)
1 (3.3)
1 (1.8)
1 (3.3)
2 (3.6)
1 (3.3)
0
0
2 (3.6)
1 (3.3)
0
0
0
0
0.579
0.653
Values are presented as number (%).
Hypo-IMRT, hypofractionated intensity-modulated radiotherapy; CF-3DRT, conventionally fractionated radiotherapy; RTOG, Radiation 
Therapy Oncology Group; GU, genitourinary; GI, gastrointestinal.
a)Toxicity that developed ≥90 days after completion of radiotherapy.
Table 5. Analysis of variables affecting late genitourinary and gastrointestinal toxicity
Variable
Late GU ≥ grade 2 Late GI ≥ grade 2
OR (95% CI) p-value OR (95% CI) p-value
Age (yr)
DM
Anticoagulant use
Hemorrhoid
BPH
ADT
Acute GU toxicity
Acute GI toxicity
Risk group
EQD1.8 Gy3
Rectal balloon
RT field
≥70 vs. <70
Yes vs. no
Yes vs. no
Yes vs. no
Yes vs. no
Yes vs. no
Yes vs. no
Yes vs. no
Low vs. intermediate
Intermediate vs. high
81 vs. 70.2
First vs. at cone down
Prostate vs. whole pelvis
-
-
-
-
-
-
  1.758 (0.251–12.330)
-
-
  3.294 (0.195–55.511)
0.527 (0.032–8.741)
0.527 (0.032–8.741)
  0.787 (0.048–13.012)
0.998
0.998
0.998
0.999
0.997
0.998
0.570
-
0.999
0.408
0.655
0.655
0.867
  2.413 (0.238–19.332)
-
0.800 (0.087–7.335)
  5.133 (0.449–58.732)
-
1.721 (0.298–9.937)
-
2.547 (0.983–6.602)
  2.750 (0.227–33.276)
  5.500 (0.841–35.975)
1.077 (0.186–6.250)
1.077 (0.186–6.250)
  0.787 (0.048–13.012)
0.497
0.998
0.844
0.188
-
0.544
-
0.054
0.426
0.075
0.934
0.934
0.867
ADT, androgen deprivation therapy; BPH, benign prostate hyperplasia; CI, confidence interval; DM, diabetes mellitus; EQD1.8 Gy3, 1.8 Gy-
equivalent dose, assuming an α/β of 3 Gy; GI, gastrointestinal; GU, genitourinary; OR, odds ratio; RT, radiotherapy.
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escalations of higher than 10 Gy in conventional fractionation 
might increase BRFS of prostate cancer patients. However, 
treatments using conventional fractionation exceeding 75–80 
Gy require a long treatment period (7–8 weeks); and Thames 
et al. [12] reported that this prolonged overall treatment 
time reduced the BRFS. On the other hand, prostate cancer is 
characterized by a low α/β ratio and slow cell kinetics [4,5], 
whereas the rectum, which is adjacent to the prostate, has 
a relatively high α/β  ratio [6]; therefore, hypofractionation 
would be beneficial. As such, if the biological effective dose, 
which is similar to the conventionally escalated total dose, is 
applied during a hypofractionated treatment schedule, we can 
expect a high BRFS along with a reduced treatment period. 
However, as no firm optimal dose scheme has been specified, 
various dose-escalated hypofractionation schemes have been 
attempted by different institutions [13-17]. Since the early 
2000s, patients undergoing IMRT at our institute have received 
radiation treatments comprising a total dose of 70 Gy in 2.5-Gy 
fractions, or dose-escalated hypofractionated regimens.
  Although opinions vary with respect to the correct α/β ratio 
for prostate cancer, Oliveira et al. [4] estimated this value as 
approximately 2.7 Gy based on their literature review. In our 
study, the α/β ratio was set to 3 Gy in order to convert the 
biological equivalent doses for comparisons of treatment 
outcomes and toxicities. The regimen comprising 70 Gy 
in 2.5-Gy fractions used in our study was delivered at an 
equivalent dose of 1.8 Gy per fraction (EQD1.8) of 81 Gy3. In 
other studies in which the total biological equivalent doses 
also exceeded 80 Gy EQD1.8 [13-15,17,18], the BRFS rates for 
low-, intermediate-, and high-risk patients ranged between 
94%–98%, 83%–100%, and 71%–85%, respectively. Most 
of these studies reported better BRFS rates relative to the 
other arms, in which patients received doses of approximately 
70 Gy, and our study also reconfirmed that the Hypo-IMRT 
group experienced better results than the CF-3DRT group, 
which was prescribed a dose of only 70.2 Gy. Specifically, 
the 5-year low-, intermediate-, and high-risk BRFS rates were 
100%, 100%, and 88.5%, respectively in this study. Based on 
the treatment results obtained according to the institutional 
protocols investigated to date, the present scheme appears 
sufficient for low- to intermediate-risk patients, while some 
limitations still exist for high-risk patients. Therefore, to reduce 
these failures, further dose-escalation trials using external-
beam radiotherapy dose increases or combination therapy 
including brachytherapy should be conducted.
  The late toxicities experienced in the dose-escalated hypo-
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fractionated trials at various institutes [14,18-25] are listed in 
Table 6. Although toxicity comparisons should be interpreted 
care fully according to the selected scale [26], studies using 
the Radiation Therapy Oncology Group scale reported that 
among cases of GU toxicity, approximately 3.0%–15.0% of 
patients developed grade 2 or higher toxicities, including a few 
cases of grade 3 toxicity; in cases of GI toxicity, approximately 
4.0%–11.0% of patients developed grade 2 or higher side 
effects. In studies involving IMRT, the late toxicity levels have 
been reported as acceptable. Accordingly, in the present study, 
although 1 patient developed a grade 3 GI toxicity in the 
Hypo-IMRT group, the percentage of patients who developed 
grade 2 or higher toxicities was low. This may be attributed 
to the use rectal balloons in our institute. This rectal balloon, 
the effectiveness of which has been previously reported by 
Teh et al. [8] and Smeenk et al. [27], acts as a fiducial marker 
in image-guided radiotherapy and can fixate the prostate 
to render it immovable. Furthermore, the balloon excludes 
the posterior rectal wall from the radiation treatment field, 
thereby exposing it to a minimal radiation dose and reducing 
the rectal toxicity. The symmetric rectal balloon designed at 
our institute can stably fixate the prostate and also features 
superior positional reproducibility in the rectum [9]. In an 
actual treatment situation, because the rectal balloon must be 
inserted for each treatment, cooperation between the patient 
and the radiotherapist is essential; however, with prolonged 
treatment, the patient’s compliance may decrease. By reducing 
the treatment period, hypofractionated radiotherapy is 
considered to increase the patient’s acceptance of the rectal 
balloon. 
  Currently, there is much controversy regarding whether 
elective pelvic irradiation used during prostate cancer treat-
ment can reduce pelvic nodal recurrences and whether this 
technique will positively influence the treatment outcome. 
Usually, an RSLN of 15% [11,28,29] is recommended as the 
indication for performing elective pelvic irradiation. However, 
negative elective nodal irradiation results have been recently 
reported in some randomized trials [30-32]. At our institute, 
we perform elective nodal irradiation only when the RSLN 
exceeds 30%, which is a much stricter cutoff than 15%. As 
a result, no nodal recurrence occurred in patients who did 
not undergo pelvic nodal irradiation; and, interestingly, an 
RSLN of 30% was found to be the main prognostic factor for 
BRFS. Mantini et al. [33] reported that patients with high-risk 
nodal involvement (>30% RSLN) who underwent whole pelvis 
radiotherapy exhibited statistically significant improvements in 
disease-free survival relative to those receiving prostate-only 
radiotherapy. 
  Although this study was conducted according to a consistent 
dose scheme and target definition, it has some limitations, 
owing to the relatively small number of patients compared 
with those included in Western reports, as well as the 
retrospective nature of the study.
  In conclusion, the results of the present study revealed an 
increase in the BRFS resulting from the use of a dose-escalated 
hypofractionation dose scheme; along with the maintenance 
of a low toxicity rate, owing to the use of a customized rectal 
balloon together with IMRT. 
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